TRACON Pharmaceuticals, Inc. (TCON) has issued an announcement.
David Lazar has been appointed as the Chief Business Development Officer for TRACON Pharmaceuticals, effective May 7, 2024. Bringing a robust background as CEO of multiple companies, Lazar’s new role includes spearheading business development, strategic planning, and finance, with direct reporting to the CEO. His compensation includes a generous monthly salary plus potential bonuses tied to company valuation increases, along with severance benefits under certain conditions. Lazar’s selection was independent of any other agreements and he has no familial ties to the current board or executive officers of the company.
Learn more about TCON stock on TipRanks’ Stock Analysis page.
